These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25424929)

  • 21. A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity.
    Wu JY; Zhang W; Pu J; Liu Y; Huang LL; Zhou Y; Gao JM; Tan JB; Liu XL; Yang J; Lin XC; Feng GW; Yin N; Chen R; Hu XQ; Yi S; Ye J; Kuang XJ; Wang Y; Zhang GM; Sun MS; Wang YX; Hu ZY; Yang JS; Li HJ
    Vaccine; 2024 Jul; 42(19):4030-4039. PubMed ID: 38796326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.
    Cunliffe NA; Witte D; Ngwira BM; Todd S; Bostock NJ; Turner AM; Chimpeni P; Victor JC; Steele AD; Bouckenooghe A; Neuzil KM
    Vaccine; 2012 Apr; 30 Suppl 1(0 1):A36-43. PubMed ID: 22520135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
    Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants.
    Dhingra MS; Kundu R; Gupta M; Kanungo S; Ganguly N; Singh MP; Bhattacharya MK; Ghosh R; Kumar R; Sur D; Chadha SM; Saluja T
    Vaccine; 2014 Aug; 32 Suppl 1():A117-23. PubMed ID: 25091664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
    Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
    Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.
    Shin S; Anh DD; Zaman K; Yunus M; Mai le TP; Thiem VD; Azim T; Victor JC; Dallas MJ; Steele AD; Neuzil KM; Ciarlet M
    Vaccine; 2012 Apr; 30 Suppl 1():A106-13. PubMed ID: 22520119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh.
    Feller AJ; Zaman K; Lewis KD; Hossain I; Yunus M; Sack DA
    Vaccine; 2012 Apr; 30 Suppl 1():A101-5. PubMed ID: 22520118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Tolerability and Immunogenicity of Pentavalent Rotavirus Vaccine Manufactured by a Modified Process.
    Martinón-Torres F; Greenberg D; Varman M; Killar JA; Hille D; Strable EL; Stek JE; Kaplan SS
    Pediatr Infect Dis J; 2017 Apr; 36(4):417-422. PubMed ID: 28141698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
    Leshem E; Givon-Lavi N; Tate JE; Greenberg D; Parashar UD; Dagan R
    Clin Infect Dis; 2016 May; 62 Suppl 2():S155-60. PubMed ID: 27059350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.
    Danchin M; Kirkwood CD; Lee KJ; Bishop RF; Watts E; Justice FA; Clifford V; Cowley D; Buttery JP; Bines JE
    Vaccine; 2013 May; 31(23):2610-6. PubMed ID: 23597719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.
    Kawamura N; Tokoeda Y; Oshima M; Okahata H; Tsutsumi H; Van Doorn LJ; Muto H; Smolenov I; Suryakiran PV; Han HH
    Vaccine; 2011 Aug; 29(37):6335-41. PubMed ID: 21640780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.
    Vesikari T; Karvonen A; Puustinen L; Zeng SQ; Szakal ED; Delem A; De Vos B
    Pediatr Infect Dis J; 2004 Oct; 23(10):937-43. PubMed ID: 15602194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial.
    Lau YL; Nelson EA; Poon KH; Chan PK; Chiu S; Sung R; Leung CW; Ng D; Ma YM; Chan D; Lee TL; Tang J; Kwan YW; Ip P; Ho M; Fung LW; Tang H; Suryakiran PV; Han HH; Bock H;
    Vaccine; 2013 Apr; 31(18):2253-9. PubMed ID: 23499605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.
    Rodriguez ZM; Goveia MG; Stek JE; Dallas MJ; Boslego JW; DiNubile MJ; Heaton PM
    Pediatr Infect Dis J; 2007 Mar; 26(3):221-7. PubMed ID: 17484218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I clinical trial of a new 5-valent rotavirus vaccine.
    Luna EJ; Frazatti-Gallina NM; Timenetsky MC; Cardoso MR; Veras MA; Miraglia JL; Escobar AM; Grisi SJ; Raw I; Precioso AR
    Vaccine; 2013 Feb; 31(7):1100-5. PubMed ID: 23261048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.